吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究

目的评价吉西他滨(gemcitabine)联合顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法选择经病理证实的晚期非小细胞肺癌41例住院患者采用GP方案行静脉化疗，具体为Gemcitabine 1250mg/m^2d1、d8，DDP30mg/m^2d1-d3，21天重复，至少使用2周期以上。结果完全缓解(CR)4．9％(2／41)，部分缓解(PR)43．9％(18／41)，稳定(SD)34．1％(14／41)，进展(PD)17．00k，(7／41)，总有效率(RR)48．80%；肿瘤控制率(CR PR SD)为82．19％；中位缓解期7．1m，中位生存期11m(4．5～20m)；毒副反应以白细胞及血小板下降、消化道反应、乏力为常见，均可耐受，无化疗相关死亡。结论吉西他滨联合顺铂对晚期非小细胞肺癌有较好疗效，毒副反应可以耐受，值得临床推广。

Combined gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer

Objective To evaluate the clinical efficacy and toxicity of advanced non-small cell lung cancer (NSCLC) treated by combined gemcitabine and cisplatin. Methods Forty-one patients with advancd NSCLC enrolled in alloted to the study. The patients received gemcitabine 1250mg/m~2 on d1, d8 and cisplatin 30mg/ m~2 on d1~d3 in the 21-day cycle. Results An objective response was obtained in 48.8%(RR 20/41) of patients (2 CR and 18 PR), whereas 14 patients had setable disease and 7patients showed progressive disease. The cancer control rate was 82.9%(CR+PR+NC). The median response duration was 7.1 months and the median survival duration was 11.0 months. The main toxicities were leukopenia, thrombocytopenia,gastro-intertinal reaction and weakness. Conclusion The combination of gemcitabine and cisplatin, being feasible and well-tolerated, should be taken as an energetic scheme in the treatment of advanced NSCLC.